Assuntos
Neoplasias/diagnóstico por imagem , Adulto , Feminino , Humanos , Pessoa de Meia-Idade , Medicina Nuclear , CintilografiaRESUMO
We studied cellular immune (total lymphocytes, lymphocytary populations and delay hypersensitivity skin tests) and humoral (immunoglobulins and complement) response, as well as nutritional status (anthropometric and biochemical para meters), antitumoral treatment. The effect of tumoral extension, nutritional status and age on immunity was assessed. We have demonstrated a poor relationship between the cellular immunological response and the extension of neoplasia, a moderate effect of age and a significant impact of nutritional status.
Assuntos
Neoplasias/imunologia , Fatores Etários , Idoso , Humanos , Contagem de Leucócitos , Linfócitos , Pessoa de Meia-Idade , Metástase Neoplásica , Neoplasias/metabolismo , Neoplasias/patologia , Estado Nutricional , Estudos ProspectivosRESUMO
A case of hemispheric medulloblastoma of cerebellum in a 22 male patient is presented. The patient complained of headache and an intracranial hypertension syndrome progressively appeared. Diagnosis was established by CT scan. Treatment consisted of radical surgery associated to radiotherapy and chemotherapy. Present survival with this treatment is 4 years being the patient asymptomatic and without signs of relapse.
Assuntos
Neoplasias Cerebelares/diagnóstico , Meduloblastoma/diagnóstico , Adulto , Neoplasias Cerebelares/terapia , Terapia Combinada , Humanos , Masculino , Meduloblastoma/terapia , Tomografia Computadorizada por Raios XRESUMO
A case of primary lymphoma of the central nervous system treated successfully with radiotherapy and systemic and intrathecal chemotherapy is described. The efficiency of the combination of radiotherapy with chemotherapy in the treatment of primary lymphoma of the central nervous system is discussed.
Assuntos
Neoplasias Encefálicas/tratamento farmacológico , Neoplasias Encefálicas/radioterapia , Linfoma de Células B/tratamento farmacológico , Linfoma de Células B/radioterapia , Terapia Combinada , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
56 female patients with breast carcinoma and treated with polychemotherapy: adriamycin, vindesine, ciclophosphamide and 5-fluorouracil were studied, divided in three groups with different antiemetic schedule: group A 40 mg/iv of metoclopramide; group B 40 mg iv of metoclopramide and 125 mg/iv of methylprednisolone before beginning chemotherapy; and group C 2 mg/oral of lorazepam, 125 mg/iv methyl-prednisolone and 1 mg/kg/oral of metoclopramide previously to begin chemotherapy; at two and four hours of the first dose, metoclopramide was repeated the same doses (really) three doses each two hours. The combination of methylprednisolone-metoclopramide (B), decreases significantly the intensity, duration and frequency of nausea and vomiting, achieving total protection (no vomiting) in 4.34% of cycles of chemotherapy in group A, 32.2% in group B and 30.2% in group C (p less than 0.005 group A versus group B and A versus group C). Also we observed, without statistical analysis, better subjective tolerance to chemotherapy in patients receiving lorazepam associated to schedule B (schedule C). This makes it the recommended schedule.